Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype.
cognition
multiple sclerosis
neuropsychology
secondary progressive MS
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
29 Jan 2022
29 Jan 2022
Historique:
received:
12
01
2022
revised:
21
01
2022
accepted:
24
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Cognitive deficits are common in multiple sclerosis (MS) and affect patients at all stages of the disease, regardless of phenotype. This literature review focuses the cognitive deficits observed in secondary progressive MS (SPMS). It is mainly based on studies that compared the frequency and main characteristics of cognitive deficits in SPMS with other phenotypes. A bibliographic search was carried out using the PubMed database with the following keywords: multiple sclerosis, secondary-progressive, cognition. Thirteen studies were initially selected that were published in English, reporting the neuropsychological data of a sample of at least 30 patients with SPMS, comparing them with patients with other phenotypes. Studies suggest that there is an association between the duration of the disease and the frequency and extent of the cognitive disorders. Studies also showed that the SP form is associated with an increased frequency of cognitive impairment and with an increased severity as compared to relapsing-remitting MS (RRMS). Compared to RRMS, progressive forms of MS are associated with more severe impairment in certain cognitive areas, such as episodic verbal memory, information processing speed, working memory, or verbal fluency. Two studies showed that cognitive performances decline overtime in SPMS. Cognitive disorders are more frequent and more severe in the SP form than in relapsing course of MS. The profile of cognitive impairment encountered in the SP form also appears to be different from those found in the other phenotypes.
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive deficits are common in multiple sclerosis (MS) and affect patients at all stages of the disease, regardless of phenotype.
AIMS
OBJECTIVE
This literature review focuses the cognitive deficits observed in secondary progressive MS (SPMS). It is mainly based on studies that compared the frequency and main characteristics of cognitive deficits in SPMS with other phenotypes.
METHODS
METHODS
A bibliographic search was carried out using the PubMed database with the following keywords: multiple sclerosis, secondary-progressive, cognition.
RESULTS
RESULTS
Thirteen studies were initially selected that were published in English, reporting the neuropsychological data of a sample of at least 30 patients with SPMS, comparing them with patients with other phenotypes. Studies suggest that there is an association between the duration of the disease and the frequency and extent of the cognitive disorders. Studies also showed that the SP form is associated with an increased frequency of cognitive impairment and with an increased severity as compared to relapsing-remitting MS (RRMS). Compared to RRMS, progressive forms of MS are associated with more severe impairment in certain cognitive areas, such as episodic verbal memory, information processing speed, working memory, or verbal fluency. Two studies showed that cognitive performances decline overtime in SPMS.
CONCLUSION
CONCLUSIONS
Cognitive disorders are more frequent and more severe in the SP form than in relapsing course of MS. The profile of cognitive impairment encountered in the SP form also appears to be different from those found in the other phenotypes.
Identifiants
pubmed: 35203948
pii: brainsci12020183
doi: 10.3390/brainsci12020183
pmc: PMC8870031
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Mult Scler Relat Disord. 2021 Feb;48:102692
pubmed: 33352358
Mult Scler Relat Disord. 2014 Jul;3(4):463-72
pubmed: 25877058
Neurology. 2004 Jul 27;63(2):335-9
pubmed: 15277630
J Neurol Sci. 2006 Jun 15;245(1-2):187-94
pubmed: 16643951
Front Neurol. 2017 Nov 28;8:643
pubmed: 29234305
J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):519-26
pubmed: 15774439
Brain. 2018 Sep 1;141(9):2605-2618
pubmed: 30169585
Arch Neurol. 2001 Oct;58(10):1602-6
pubmed: 11594918
Neurology. 2013 Apr 16;80(16):1501-8
pubmed: 23516324
J Int Neuropsychol Soc. 2006 Jul;12(4):549-58
pubmed: 16981607
Mult Scler. 2020 Nov;26(13):1740-1751
pubmed: 31603042
Neurology. 2021 Aug 24;97(8):378-388
pubmed: 34088878
Eur J Neurol. 2016 Feb;23(2):282-9
pubmed: 25903918
Neurol Res. 2013 Oct;35(8):867-72
pubmed: 23816638
Med Sci Monit. 2017 Feb 01;23:588-597
pubmed: 28145395
Eur J Neurol. 2010 Mar;17(3):499-505
pubmed: 20050887
Mult Scler. 2017 Aug;23(9):1258-1267
pubmed: 27738090
PLoS One. 2013 Aug 01;8(8):e71058
pubmed: 23936485
J Neuropsychol. 2020 Sep;14(3):347-369
pubmed: 32056386
Neurol Sci. 2016 Sep;37(9):1475-81
pubmed: 27207679
Front Neurol. 2019 Mar 20;10:261
pubmed: 30949122